Regulated cell death (RCD) is a universal process in living organisms that is essential for tissue homeostasis or to the restoration of biological equilibrium following stress. Ferroptosis is a specific nonapoptotic cell death that is dependent on iron and is very different from other forms of RCD. Ferroptosis can affect the development of liver diseases such as drug-induced liver injury (DILI), liver fibrosis, and hepatocellular carcinoma (HCC) by regulating the level of intracellular iron, the production of intracellular reactive oxygen species, and lipid peroxides. In this review, we summarize the current knowledge of ferroptosis, in terms of discovery, history, characteristics, mechanism, and the factors regulating liver diseases. We discuss how these factors and signaling pathways change in the context of liver disease. Furthermore, we focus on delineating the roles of effective therapeutic drugs or compounds in liver disease. In summary, we discuss the role of ferroptosis in liver disease, providing a strategy and new ideas for preventing liver disease, finding new therapeutic targets, and reducing liver damage.

调节性细胞死亡（RCD）是活生物体中的普遍过程，对于组织稳态或应激后恢复生物平衡至关重要。Ferroptosis是一种特定的非凋亡性细胞死亡，它依赖于铁并且与其他形式的RCD有很大不同。Ferroptosis可通过调节细胞内铁的水平，细胞内活性氧的产生和脂质过氧化物来影响肝脏疾病的发展，例如药物性肝损伤（DILI），肝纤维化和肝细胞癌（HCC）。在这篇综述中，我们从发现，病史，特征，机制以及调节肝病的因素方面总结了目前有关肥大症的知识。我们讨论了在肝病的背景下这些因素和信号通路如何变化。此外，我们致力于描述有效的治疗药物或化合物在肝病中的作用。总之，我们讨论了肥大症在肝病中的作用，提供了预防肝病，寻找新的治疗靶点并减少肝损伤的策略和新思路。